PURPOSE OF REVIEW: We review the clinical trials and observational studies literature regarding the clinical and economic burden of bone metastasis and skeletal-related events (SREs) in prostate cancer, and discuss current gaps in understanding the impact of bone metastasis in this disease. RECENT FINDINGS: Trial data indicate that SREs occur in half of prostate cancer patients with bone metastasis in the absence of treatment, and 30-45% among those who receive bone-modifying agents. In the United States, the cost of SRE ranged from $7553 per radiation episode to $88 838 per bone surgery episode. Prevalence of SRE, time to SRE occurrence, and cost of SRE varied across studies because of differences in study populations, follow-up period, and the algorithm used to measure SRE. There is limited evidence on the clinical and economic impact by SRE subtype. Information regarding patient-reported outcomes and costs from the patient's perspective is lacking. SUMMARY: Bone metastasis and SREs in prostate cancer patients are associated with considerable morbidity, reduced survival, and substantial economic burden. Consistent study methodology, particularly the measurement of SREs, is necessary to allow comparison of estimates across studies. The inclusion of patient-centered clinical and economic outcomes in future research will provide pertinent information regarding the burden of bone metastasis and SREs.
PURPOSE OF REVIEW: We review the clinical trials and observational studies literature regarding the clinical and economic burden of bone metastasis and skeletal-related events (SREs) in prostate cancer, and discuss current gaps in understanding the impact of bone metastasis in this disease. RECENT FINDINGS: Trial data indicate that SREs occur in half of prostate cancerpatients with bone metastasis in the absence of treatment, and 30-45% among those who receive bone-modifying agents. In the United States, the cost of SRE ranged from $7553 per radiation episode to $88 838 per bone surgery episode. Prevalence of SRE, time to SRE occurrence, and cost of SRE varied across studies because of differences in study populations, follow-up period, and the algorithm used to measure SRE. There is limited evidence on the clinical and economic impact by SRE subtype. Information regarding patient-reported outcomes and costs from the patient's perspective is lacking. SUMMARY: Bone metastasis and SREs in prostate cancerpatients are associated with considerable morbidity, reduced survival, and substantial economic burden. Consistent study methodology, particularly the measurement of SREs, is necessary to allow comparison of estimates across studies. The inclusion of patient-centered clinical and economic outcomes in future research will provide pertinent information regarding the burden of bone metastasis and SREs.
Authors: Eberechukwu Onukwugha; Jinani Jayasekera; James Gardner; Sana Malik; C Daniel Mullins; Arif Hussain; Jay P Ciezki; Chandana A Reddy; Brian Seal; Adriana Valderrama; Young Kwok Journal: JCO Clin Cancer Inform Date: 2018-12
Authors: Jean A McDougall; Aasthaa Bansal; Bernardo H L Goulart; Jeannine S McCune; Andy Karnopp; Catherine Fedorenko; Stuart Greenlee; Adriana Valderrama; Sean D Sullivan; Scott D Ramsey Journal: Oncologist Date: 2016-02-10
Authors: Anas Nooh; Yu Ling Zhang; Daisuke Sato; Derek H Rosenzweig; Sébastien Tabariès; Peter Siegel; Jake E Barralet; Michael H Weber Journal: J Bone Oncol Date: 2017-01-13 Impact factor: 4.072